Drug intelligence / Profile preview

cyclosporine A + sodium hyaluronate

Development stage: Unknown
Modality: Small Molecules
Administration: Ophthalmic

Overview

A combination ophthalmic medication consisting of cyclosporine A and sodium hyaluronate used primarily for the treatment of dry eye syndrome (DES). Cyclosporine A functions as an anti-inflammatory and immunomodulatory agent, while sodium hyaluronate provides lubrication and hydration to the ocular surface. Together, they create a synergistic effect that improves tear film stability, alleviates DES symptoms, reduces ocular inflammation, and enhances overall ocular comfort.

Brand names: Cyporin NNew Hyaluni
Other names: cyclosporin-A + sodium hyaluronatecyclosporine A + sodium hyaluronatecyclosporine + hyaluronic acid

Targets

PPIA (Peptidyl-prolyl cis-trans isomerase A)

Beyond the preview

Go deeper on cyclosporine A + sodium hyaluronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine A + sodium hyaluronate.

Explore the full profile